Article Tools
Add to My Bookmarks
Adds Article to your Entrepreneur Assist Bookmark page.
GlaxoSmithKline (Research Triangle Park, NC) and ChemoCentryx
(Mountain View, CA) formed a worldwide multitarget strategic alliance to
discover, develop, and market novel medicines for the treatment of a
variety of inflammatory disorders. GlaxoSmithKline will have access to
select chemokine-based therapeutics, and will issue ChemoCentryx an
upfront payment of $63.5 million in cash and series D financing, along
with research funding and potential milestone payments of up to $1.5
billion.
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: